Nicolas Marcoux MD, FRCPC

Med onc and hematologist at @chudequebec with focus on lung cancer. Tweets in English for sake of conversation, mais toujours heureux de parler français!

[Dana-Farber @DanaFarber]

Please join us in congratulating Alice Shaw, MD, PhD, on being named our next Chair of the Department of Medical Oncology.

As Chair of the Department of Medical Oncology, Shaw will oversee more than 300 faculty and more than 80 cancer research laboratories, and will drive the strategic direction for the department’s clinical, research and educational initiatives.

Learn more: https://t.co/NVQjGKZgaD

[Normand Blais, MD @NormandBlais]

Ce que j’apprends en congrès 🥲 #ASCO25

[Jill Feldman @jillfeldman4]

I just heard huge news that needs to be celebrated!
Today marks 40 years of research and care for Dr Mark Kris @MSKCancerCenter

Dr Kris has been a champion for innovative research, playing a pivotal role in many advancements over the past 4 decades. His contributions to science have transformed lung cancer care nationally and internationally. Dr Kris has consistently pushed boundaries as a founder of the Lung Cancer Mutation Consortium and a pioneer in advocating for dose optimization, anti-nausea protocols before chemotherapy, and supportive care (when many considered side effects a trade-off for longer life).

He mentored generations of oncologists who now lead departments and run major trials. Most importantly, he gave hope to patients and families when there wasn't much if any (many years).

Thank you, Dr. Kris, for your tireless efforts and dedication to improving survival and quality of life for people diagnosed with lung cancer and our families!
#LCSM

[Nicolas Marcoux MD, FRCPC @NickMarcouxMD]

You can always count on @tompowles1 to make a Q&A session interesting and dynamic! Lively discussions like this going on in many cancer centers since ESMO24 to determine the best way forward for periop tx of MIBC #GU25

[Stephen V Liu, MD @StephenVLiu]

Phase I study of TY-9591 (asandeutertinib) for #EGFR NSCLC @JTOonline. Asandeutertinib is a deuterium stabilized osimertinib derivative which in theory should provide more stability, fewer active metabolites, less toxicity. No DLTs, MTD not reached.

https://t.co/MBJsh70MmO

[Nicolas Marcoux MD, FRCPC @NickMarcouxMD]

Un hommage bien mérité pour un collègue d’exception. Un mentor depuis ma première année de médecine, avec qui j’ai la chance de travailler au quotidien maintenant! Merci pour tout ce que tu fais pour les patients au quotidien

https://t.co/TsB5DBzUn9

[Nicolas Marcoux MD, FRCPC @NickMarcouxMD]

Merci @NormandBlais de mettre en valeur notre belle gang! On est une grande famille qui traitons le cancer du poumon au Québec et le RESOT n’existerait pas sans ton implications #clcco #lcsm

[Nicolas Marcoux MD, FRCPC @NickMarcouxMD]

@NormandBlais @fans_murakami Je viens de commencer 1Q84. Merci de la recommandation!

[Stephen V Liu, MD @StephenVLiu]

Results from TROPION-Lung05 @JCO_ASCO: single arm phase II trial of datopotamab deruxtecan (TROP2 ADC) in NSCLC with an actionable genomic alteration (n=137) post TKI and chemo. RR 35.8% overall (43.6% in #EGFR, 23.5% in #ALK) with DOR 7m, DCR 78.8%.

https://t.co/z3rsqmh78C

[Yüksel Ürün @DrYukselUrun]

🧬🩸Exciting update! LB-RECIST introduces a new era for evaluating tumor response using liquid biopsy (ctDNA), addressing limits of imaging in solid tumors. A step toward precision oncology!

#LiquidBiopsy #Oncology #PrecisionMedicine #ESMO @OncoAlert @jlb_islb @ChristianRolfo @VivekSubbiah
@curijoey @isliquidbiopsy @Annals_Oncology @myESMO

https://t.co/53dHAQ4DW5

[Stephen V Liu, MD @StephenVLiu]

Will have to wait a bit longer for subcutaneous amivantamab. FDA issues complete response letter to application - not based on efficacy or safety, rather related to “observations as part of a standard pre-approval inspection at a manufacturing facility.”

https://t.co/KcL7fPRVKI

[Lea Alhilali, MD @teachplaygrub]

1/Do radiologists sound like they are speaking a different language when they talk about MRI?

T1 shortening what? T2 prolongation who?

Here’s a translation w/an introductory thread to MRI.

[Nicolas Marcoux MD, FRCPC @NickMarcouxMD]

The end of DD-MVAC? For me yes! Long live periop cis-gem-durva in MIBC (until we do even better!) Great talk by @tompowles1 as usual! #ESMO24

[Nicolas Marcoux MD, FRCPC @NickMarcouxMD]

Always nice to see @CDNCancerTrials trials on the big stage, even when the results are not what everyone wished for… good job to all the investigators #lcsm #ESMO2024

[Nicolas Marcoux MD, FRCPC @NickMarcouxMD]

What…A… Stage! Wow @KNiewiadoma @LeTourFemmes

[Stephen V Liu, MD @StephenVLiu]

Two cases of de novo #SCLC with #EGFR exon 20 insertions highlight challenges of the current era - both cases had some response to taxanes, one improved with amivantamab. Tip of the iceburg here from Drs. @LodovicaZullo @BenjaminBesseMD @mihaela_aldea

https://t.co/1EpPjFotPz

[Stephen V Liu, MD @StephenVLiu]

Myopathy is an underappreciated toxicity of the #EGFR TKI osimertinib. In my experience, more of a later event. In this @JTOonline report, biopsy suggests a non-inflammatory mechanism. May impact myocyte protein synthesis & mitochondrial dysfunction.

https://t.co/FeCk4UPpUG

[Nicolas Marcoux MD, FRCPC @NickMarcouxMD]

@jakelee0711 @BWFUND Congrats!

[Nicolas Marcoux MD, FRCPC @NickMarcouxMD]

While many of us are still amazed by the updated PFS results from CROWN, important data included regarding outcomes after dose adjustment . Tox can be tricky, individualizing the dose is important! #ASCO24

[Jill Feldman @jillfeldman4]

As we anxiously await data to read out at #ASCO24, please remember, People Come First!
@MaryBoulanger4 will present her work that highlights prognostic communication challenges & patients' unmet psychosocial needs - both JUST AS IMPORTANT as OS & HR's.
https://t.co/KDEqiNMUw4